Recommendations for benchmarking preclinical studies of nanomedicines

Abstract

Nanoparticle-based delivery systems provide newopportunities to overcome the limitations associated with traditional smallmolecule drug therapy for cancer and to achieve both therapeutic and diagnostic functions in the sameplatform. Preclinical trials are generally designed to assess therapeutic potential and not to optimize the design of the delivery platform. Consequently, progress in developing design rules for cancer nanomedicines has been slow, hindering progress in the field. Despite the large number of preclinical trials, several factors restrict comparison and benchmarking of different platforms, including variability in experimental design, reporting of results, and the lack of quantitative data. To solve this problem, we review the variables involved in the design of preclinical trials and propose a protocol for benchmarking that we recommend be included in in vivo preclinical studies of drugdelivery platforms for cancer therapy. This strategy will contribute to building the scientific knowledge base that enables development of design rules and accelerates the translation of new technologies.